SERA News & Events

Sera Prognostics announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs, PRIME, study were accepted for publication in a peer-reviewed journal. The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's, SMFM, annual meeting. "We look forward to sharing PRIME manuscript data upon publication at upcoming medical meetings and through events with our research analysts," said Zhenya Lindgardt, President and CEO of Sera Prognostics.

Sera Prognostics announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Anderson has a proven track record of driving business growth and enhancing sales strategies in the healthcare sector.

Sera Prognostics announced that Jeff Elliott will join its Board of Directors on March 20. Ryan Trimble-after 14 years serving Sera, its customers and its shareholders- has informed the company of his intention to retire and step down as a director effective June 30. Marcus Wilson also informed the company that he will not stand for re-election at the end of his term at the company's 2025 Annual Meeting of Stockholders. Elliott is currently a senior advisor at Boston Consulting Group and also serves on the board of directors of Quanterix, a publicly traded life science research tools and diagnostics company. Prior to these roles, Elliott served as CFO of Exact Sciences from 2016 through May 2024 and also as COO from 2021 through 2023. Prior to his appointment as CFO, Elliott served as Exact Sciences' VP, strategy and business development. From 2007 to 2016, Elliott was with Robert Baird & Co. where he was a senior equity research analyst covering healthcare companies.